Publications by authors named "N Okita"
Background: Small bowel adenocarcinoma (SBA) is a rare malignancy with few established chemotherapy options and a dismal prognosis. We investigated the expression of claudin 18.2, nectin-4, human epidermal growth factor receptor 3 (HER3), and programmed death-ligand 1 (PD-L1) in SBA to identify potential antibody drug targets and analyzed associated clinicopathological features and prognosis.
View Article and Find Full Text PDFBackground: Claudin-18 isoform 2 (CLDN18.2) is expressed in multiple cancers and is a promising target for antitumor therapy. However, there is limited knowledge regarding the prevalence and characteristics of CLDN18.
View Article and Find Full Text PDFPurpose: Clinical utility of comprehensive genomic profiling (CGP) for precision medicine has become evident. Although there are several reports on the genomic landscape of GI stromal tumors (GISTs), large-scale data specific to GIST are limited, especially in Asia. Additionally, the applicability of molecular-targeted agents identified using CGP has not been extensively examined.
View Article and Find Full Text PDFImatinib may be a useful targeted agent for patients with advanced gastric adenocarcinoma who have KIT mutations.
View Article and Find Full Text PDFArticle Synopsis
- - Programmed cell death-1 (PD-1) blockade improves survival rates in patients with advanced esophageal squamous cell carcinoma (ESCC), but its effect on subsequent taxane treatments is uncertain.
- - A study of 99 advanced ESCC patients treated with taxanes (paclitaxel or docetaxel), some with prior PD-1 blockade, found that those previously exposed had a significantly higher objective response rate (37.5%) compared to those who were naïve (13.4%).
- - Despite the higher response rate, the progression-free survival duration was similar for both groups (3.8 months for the Exposed vs. 2.8 months for the Naïve), and serious adverse